Nadir Yehya1, Sabah Servaes, Neal J Thomas, Vinay M Nadkarni, Vijay Srinivasan. 1. Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia and University of Pennsylvania, Suite 7C-26, 34th Street and Civic Center Boulevard, Philadelphia, PA, 19104, USA, yehyan@email.chop.edu.
Abstract
PURPOSE: Use of systemic corticosteroids in acute respiratory distress syndrome (ARDS) remains controversial, and studies in children are lacking. METHODS: We performed an observational, single-center study in a prospectively enrolled cohort of children meeting criteria for ARDS (both Berlin 2012 and AECC 1994 acute lung injury) and pediatric ARDS (PARDS, as defined by PALICC 2015). Comprehensive analysis of corticosteroid utilization was planned, and detailed information collected on corticosteroid use, timing, treatment duration, and cumulative dose while mechanically ventilated. We assessed the association between corticosteroid exposure >24 h and outcomes. RESULTS: Of the 283 children with PARDS (37 deaths, 13%), 169 (60%) received corticosteroids for >24 h while ventilated: 51% hydrocortisone, 41% methylprednisolone, 5% dexamethasone, 3% combination of corticosteroids. Corticosteroid exposure >24 h was associated with increased mortality, fewer ventilator-free days at 28 days (VFD), and longer duration of ventilation in survivors in unadjusted analyses (all p < 0.05). Multivariate and propensity score adjusted analyses confirmed independent association of corticosteroid exposure with fewer VFD and longer duration of ventilation in survivors, but not with mortality. In planned analyses of high-risk subgroups, no benefit was seen with corticosteroids exposure, with fewer VFD associated with corticosteroid exposure >24 h in patients with ≥3 organ failures and immunocompromised patients. CONCLUSIONS: Corticosteroid exposure >24 h was independently associated with fewer VFD and longer duration of ventilation in survivors, even after adjustment for key potential confounders, including severity of illness, oxygenation index, immunocompromised status, and number of organ failures.
PURPOSE: Use of systemic corticosteroids in acute respiratory distress syndrome (ARDS) remains controversial, and studies in children are lacking. METHODS: We performed an observational, single-center study in a prospectively enrolled cohort of children meeting criteria for ARDS (both Berlin 2012 and AECC 1994 acute lung injury) and pediatric ARDS (PARDS, as defined by PALICC 2015). Comprehensive analysis of corticosteroid utilization was planned, and detailed information collected on corticosteroid use, timing, treatment duration, and cumulative dose while mechanically ventilated. We assessed the association between corticosteroid exposure >24 h and outcomes. RESULTS: Of the 283 children with PARDS (37 deaths, 13%), 169 (60%) received corticosteroids for >24 h while ventilated: 51% hydrocortisone, 41% methylprednisolone, 5% dexamethasone, 3% combination of corticosteroids. Corticosteroid exposure >24 h was associated with increased mortality, fewer ventilator-free days at 28 days (VFD), and longer duration of ventilation in survivors in unadjusted analyses (all p < 0.05). Multivariate and propensity score adjusted analyses confirmed independent association of corticosteroid exposure with fewer VFD and longer duration of ventilation in survivors, but not with mortality. In planned analyses of high-risk subgroups, no benefit was seen with corticosteroids exposure, with fewer VFD associated with corticosteroid exposure >24 h in patients with ≥3 organ failures and immunocompromised patients. CONCLUSIONS: Corticosteroid exposure >24 h was independently associated with fewer VFD and longer duration of ventilation in survivors, even after adjustment for key potential confounders, including severity of illness, oxygenation index, immunocompromised status, and number of organ failures.
Authors: Hector R Wong; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Scott L Weiss; Thomas P Shanley; Michael T Bigham; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Jerry J Zimmerman Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Bonny B Drago; Dai Kimura; Cynthia R Rovnaghi; Andreas Schwingshackl; Mark Rayburn; G Umberto Meduri; Kanwaljeet J S Anand Journal: Pediatr Crit Care Med Date: 2015-03 Impact factor: 3.624
Authors: Yolanda López-Fernández; Amelia Martínez-de Azagra; Pedro de la Oliva; Vicent Modesto; Juan I Sánchez; Julio Parrilla; María José Arroyo; Susana Beatriz Reyes; Martí Pons-Ódena; Jesús López-Herce; Rosa Lidia Fernández; Robert M Kacmarek; Jesús Villar Journal: Crit Care Med Date: 2012-12 Impact factor: 7.598
Authors: Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie Fitzgerald; Paul A Checchia; Keith Meyer; Thomas P Shanley; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Raj S Shekhar; Shira Gertz; Emily Dawson; Kelli Howard; Kelli Harmon; Eileen Beckman; Erin Frank; Christopher J Lindsell Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: Simon Erickson; Andreas Schibler; Andrew Numa; Gabrielle Nuthall; Michael Yung; Elaine Pascoe; Barry Wilkins Journal: Pediatr Crit Care Med Date: 2007-07 Impact factor: 3.624
Authors: Adam S Himebauch; Nadir Yehya; Yan Wang; Thomas Conlon; Todd J Kilbaugh; Francis X McGowan; Laura Mercer-Rosa Journal: Crit Care Med Date: 2018-11 Impact factor: 7.598
Authors: Andreas Schwingshackl; Gianfranco Umberto Meduri; Dai Kimura; Stephania A Cormier; Kanwaljeet J S Anand Journal: Intensive Care Med Date: 2015-09-10 Impact factor: 17.440